Axios: Higher US drug prices don’t translate to better health

The United States pays far more for prescription drugs than other countries, but health outcomes aren’t much better––and sometimes, they’re worse––according to Axios.

The pharmaceutical industry frequently justifies its higher prices by arguing it provides resources for research and development. However, being unable to pay for these drugs could void that argument or at least bring up questions about why consumers have to pay so much.

At the same time, the prices do not reflect quality, or better care. The United States was ranked last in healthcare outcomes in a 2017 Commonwealth Fund report that weighted 10 other wealthy countries.

While health outcomes have yet to improve, the Trump administration continues to propose new initiatives to lower prescription drug prices in Medicare.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.